Su Hwan Kim1,2, Ji Bong Jeong1, Jinwoo Kang1, Dong-Won Ahn1, Ji Won Kim1, Byeong Gwan Kim1, Kook Lae Lee1, Sohee Oh3, Soon Ho Yoon4, Sang Joon Park4, Doo Hee Lee5. 1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea. 2. Health Care Center, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea. 3. Medical Research Collaborating Center, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea. 4. Department of Radiology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea. 5. Department of Research and Development, MEDICALIP Co, Ltd., Seoul, Korea.
Abstract
AIMS: Metabolic syndrome (MetS) increases the risk of diabetes mellitus (DM), cardiovascular disease (CVD), cancer, and mortality. Sarcopenia has been reported as a risk factor for MetS, non-alcoholic fatty liver disease, and CVD. To date, the association between sarcopenia and MetS has been investigated. However, there have been few studies on the dose-response relationship between sarcopenia and MetS. We investigated the association between sarcopenia and the prevalence of MetS. We also aimed to analyze the dose-response relationship between skeletal muscle mass and the prevalence of MetS. METHODS: We enrolled 13,620 participants from October 2014 to December 2019. Skeletal muscle mass was measured using bioelectrical impedance analysis (BIA). Appendicular skeletal muscle mass (ASM) was divided by body weight (kg) and was expressed as a percentage (ASM x 100/Weight, ASM%). The quartiles of ASM% were calculated for each gender, with Q1 and Q4 being the lowest and highest quartiles of ASM%, respectively. The quartiles of ASM% were calculated for each gender, with Q1 and Q4 being the lowest and highest quartiles of ASM%, respectively. Linear regression and logistic regression analyses were used to compare the clinical parameters according to ASM%, adjusted for age, sex, obesity, hypertension (HT), DM, dyslipidemia (DL), smoking, alcohol intake, and C-reactive protein (CRP). Multiple logistic regression analysis was performed to determine the risk of MetS in each group. RESULTS: A dose-response relationship was identified between ASM% and MetS. Sarcopenia was associated with an increased prevalence of MetS. After adjustment for age, sex, obesity, HT, DM, DL, smoking, alcohol intake, and CRP, sarcopenia remained significantly associated with MetS. For each 1 quartile increment in ASM%, the risk of MetS decreased by 56% (P< 0.001). After adjusting for age, sex, obesity, HT, DM, DL, smoking, alcohol intake, and CRP, the risk of MetS decreased by 25% per 1Q increment in ASM% (P < 0.001). CONCLUSIONS: Sarcopenia by BIA is independently associated with the risk of MetS and has a dose-response relationship.
AIMS: Metabolic syndrome (MetS) increases the risk of diabetes mellitus (DM), cardiovascular disease (CVD), cancer, and mortality. Sarcopenia has been reported as a risk factor for MetS, non-alcoholic fatty liver disease, and CVD. To date, the association between sarcopenia and MetS has been investigated. However, there have been few studies on the dose-response relationship between sarcopenia and MetS. We investigated the association between sarcopenia and the prevalence of MetS. We also aimed to analyze the dose-response relationship between skeletal muscle mass and the prevalence of MetS. METHODS: We enrolled 13,620 participants from October 2014 to December 2019. Skeletal muscle mass was measured using bioelectrical impedance analysis (BIA). Appendicular skeletal muscle mass (ASM) was divided by body weight (kg) and was expressed as a percentage (ASM x 100/Weight, ASM%). The quartiles of ASM% were calculated for each gender, with Q1 and Q4 being the lowest and highest quartiles of ASM%, respectively. The quartiles of ASM% were calculated for each gender, with Q1 and Q4 being the lowest and highest quartiles of ASM%, respectively. Linear regression and logistic regression analyses were used to compare the clinical parameters according to ASM%, adjusted for age, sex, obesity, hypertension (HT), DM, dyslipidemia (DL), smoking, alcohol intake, and C-reactive protein (CRP). Multiple logistic regression analysis was performed to determine the risk of MetS in each group. RESULTS: A dose-response relationship was identified between ASM% and MetS. Sarcopenia was associated with an increased prevalence of MetS. After adjustment for age, sex, obesity, HT, DM, DL, smoking, alcohol intake, and CRP, sarcopenia remained significantly associated with MetS. For each 1 quartile increment in ASM%, the risk of MetS decreased by 56% (P< 0.001). After adjusting for age, sex, obesity, HT, DM, DL, smoking, alcohol intake, and CRP, the risk of MetS decreased by 25% per 1Q increment in ASM% (P < 0.001). CONCLUSIONS:Sarcopenia by BIA is independently associated with the risk of MetS and has a dose-response relationship.
Authors: Seung Ha Park; Jae Hee Park; Ha Young Park; Hang Jea Jang; Hyun Kuk Kim; Jinse Park; Kyong Jin Shin; Jung Goo Lee; Young Soo Moon Journal: Clin Nutr Date: 2013-08-31 Impact factor: 7.324
Authors: Soo Lim; Jung Hee Kim; Ji Won Yoon; Seon Mee Kang; Sung Hee Choi; Young Joo Park; Ki Woong Kim; Jae Young Lim; Kyong Soo Park; Hak Chul Jang Journal: Diabetes Care Date: 2010-05-11 Impact factor: 19.112
Authors: Javed Butler; Eline A Q Mooyaart; Nina Dannemann; Fabian Bamberg; Michael D Shapiro; Maros Ferencik; Thomas J Brady; Udo Hoffmann Journal: Am J Cardiol Date: 2008-02-11 Impact factor: 2.778
Authors: Alfonso J Cruz-Jentoft; Gülistan Bahat; Jürgen Bauer; Yves Boirie; Olivier Bruyère; Tommy Cederholm; Cyrus Cooper; Francesco Landi; Yves Rolland; Avan Aihie Sayer; Stéphane M Schneider; Cornel C Sieber; Eva Topinkova; Maurits Vandewoude; Marjolein Visser; Mauro Zamboni Journal: Age Ageing Date: 2019-01-01 Impact factor: 10.668
Authors: Han Ho Jeon; Yong Kang Lee; Dong Hyun Kim; Haeyong Pak; Sang Yun Shin; Jeong Hun Seo Journal: Korean J Intern Med Date: 2020-04-29 Impact factor: 2.884
Authors: Su Hwan Kim; Hyoun Woo Kang; Ji Bong Jeong; Dong Seok Lee; Dong-Won Ahn; Ji Won Kim; Byeong Gwan Kim; Kook Lae Lee; Sohee Oh; Soon Ho Yoon; Sang Joon Park Journal: PLoS One Date: 2021-08-17 Impact factor: 3.240
Authors: Everson A Nunes; Lauren Colenso-Semple; Sean R McKellar; Thomas Yau; Muhammad Usman Ali; Donna Fitzpatrick-Lewis; Diana Sherifali; Claire Gaudichon; Daniel Tomé; Philip J Atherton; Maria Camprubi Robles; Sandra Naranjo-Modad; Michelle Braun; Francesco Landi; Stuart M Phillips Journal: J Cachexia Sarcopenia Muscle Date: 2022-02-20 Impact factor: 12.910